Mayne Pharma Group has announced receiving FDA approval to begin selling generic drugs containing morphine in the US market. The drugs, extended release tablets (MSER), are a generic version of MS Contin. MS Contin is an opiod analgesic. The extended release tablets had sales of $280 million for the 12 months preceding August 31st, 2016. Mayne Pharma is looking to expand its generic offerings in the US market.